Preclinical and first-in-human-brain-cancer applications of [ 18 F]poly (ADP-ribose) polymerase inhibitor PET/MR.

Although larger studies are necessary to confirm and further explore this tracer, we describe the promising performance of [F]PARPi as a diagnostic tool to evaluate patients with brain cancers and possible treatment-related changes.